2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
88
Neoplasm Metastasis
8
Stomach Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Brain Neoplasms
5
Pancreatic Neoplasms
4
Multiple Myeloma
4
HER2-positive Breast Cancer
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Hematologic Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Wilms Tumor
1
Uterine Neoplasms
1
Urologic Neoplasms
1
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Thyroid Neoplasms
1
Thrombocytosis
1
Solid Tumors
1
Sarcoma, Synovial
1
Sarcoma
1
Interventions
Trastuzumab
3
pyrotinib
2
pertuzumab
2
Fulvestrant
2
tucatinib
1
palbociclib
1
disitamab vedotin
1
atezolizumab
1
RC48 antibody
1
Drug Therapy
1
Docetaxel
1
Capecitabine
1
Alpelisib
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-positive Metastatic Breast Cancer
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT06595563
2026-05-07
ZEPHIR-02
Jules Bordet Institute
Phase 2
Recruiting
87 enrolled